Economic Observation Network Antu Biotech (603658) has been in a bearish trend in the past 5 days, performing weaker than the market and remaining at the industry average level. In the past 5 days, the main funds have shown a net outflow overall, with a net proportion lower than the market average. On October 14th, the main funds showed a net outflow overall, with a balanced net proportion at the market average level. The margin trading difference accounts for 1.96%.

The market attention of this stock is average, and the overall public opinion is neutral. Institutional research is frequent, and the overall research report rating has not changed much. The latest quarterly report disclosed a change of -0.12% in the holding ratio of active equity funds in this stock, and a change of -13.24% in the stock price during the same period. The company has good profitability, average growth ability, average operational ability, and average debt paying ability. The current valuation is in the historical low range and at a moderate level within the industry. The current price to earnings TTM is 18.6, which is lower than the industry median and has been at 14.96% of individual stocks in the past 5 years.

The above content is based on publicly available information and does not constitute investment advice.